Landmark Study Shows Treatment with Abbott's MitraClip ® is Superior to Medical Therapy for Advanced Heart Failure Patients with Significant Secondary Mitral Regurgitation

- The COAPT trial met both the primary safety and efficacy endpoints and all secondary endpoints, including reducing all-cause mortality through two years
Source: Abbott.com - Category: Pharmaceuticals Source Type: news